Dihydroartemisinin increases temozolomide efficacy in glioma cells by inducing autophagy

Zhang,Ze‑Shun; Wang,Jing; Shen,You‑Bi; Guo,Cheng‑Cheng; Sai,Ke; Chen,Fu‑Rong; Mei,Xin; Han,Fu; Chen,Zhong‑Ping

doi:10.3892/ol.2015.3183

Dihydroartemisinin increases temozolomide efficacy in glioma cells by inducing autophagy

Authors:
- Ze‑Shun Zhang
- Jing Wang
- You‑Bi Shen
- Cheng‑Cheng Guo
- Ke Sai
- Fu‑Rong Chen
- Xin Mei
- Fu Han
- Zhong‑Ping Chen
View Affiliations

Affiliations: Department of Neurosurgery, Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, Guangdong 510120, P.R. China, Department of Neurosurgery/Neuro‑Oncology, Sun Yat‑Sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong 510060, P.R. China
Published online on: May 6, 2015 https://doi.org/10.3892/ol.2015.3183
Pages: 379-383

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Artemisinin, a powerful antimalarial medicine, is extracted from the Chinese herb, Artemisia annua L., and has the ability to inhibit the proliferation of cancer cells. Dihydroartemisinin (DHA), the major active metabolite of artemisinin, is able to inhibit the growth of a variety of types of human cancer. However, the effect of DHA on human glioma cells remains unclear. The aim of the present study was to investigate the effect of DHA on the proliferation of glioma cells, and whether DHA was able to enhance temozolomide (TMZ) sensitivity in vitro and in vivo. In total, 10 human glioma cell lines were used to analyze the growth inhibition ability of DHA by MTT assay. The typical autophagic vacuoles were monitored by the application of the autofluorescent agent, monodansylcadaverine. Western blotting was used to detect markers of apoptosis and autophagy, namely Caspase‑3, Beclin‑1 and LC3‑B. The combination efficiency of DHA and TMZ was assessed in vitro and in vivo. The half maximal inhibitory concentration (IC50) of DHA differed among the ten human glioma cell lines. The number of autophagic vacuoles was higher in DHA‑treated SKMG‑4 cells; this was highest of all cell lines analyzed. The expression of autophagy molecular markers, Beclin‑1 and LC3‑B, was increased following DHA treatment, while no significant alteration was detected in the expression of apoptotic marker Caspase‑3. When combined with DHA, the IC50 of TMZ decreased significantly in the four glioma cell lines analyzed. Furthermore, DHA enhanced the tumor inhibition ability of TMZ in tumor-burdened mice. The results of the present study demonstrated that DHA inhibited the proliferation of glioma cells and enhanced the tumor inhibition efficacy of TMZ in vitro and in vivo through the induction of autophagy.

View Figures

View References

1	Smoll NR, Gautschi OP, Schatlo B, Schaller K and Weber DC: Relative survival of patients with supratentorial low-grade gliomas. Neuro Oncol. 14:1062–1069. 2012. View Article : Google Scholar : PubMed/NCBI
2	Nakazato Y: The 4th edition of WHO classification of tumours of the central nervous system published in 2007. No Shinkei Geka. 36:473–491. 2008.(In Japanese). PubMed/NCBI
3	Stupp R, Mason WP, van den Bent MJ, et al: National Cancer Institute of Canada Clinical Trials Group: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
4	Davis FG, McCarthy BJ, Freels S, Kupelian V and Bondy ML: The conditional probability of survival of patients with primary malignant brain tumors: Surveillance, epidemiology and end results (SEER) data. Cancer. 85:485–491. 1999. View Article : Google Scholar : PubMed/NCBI
5	Giese A, Bjerkvig R, Berens ME and Westphal M: Cost of migration: Invasion of malignant gliomas and implications for treatment. J Clin Oncol. 21:1624–1636. 2003. View Article : Google Scholar : PubMed/NCBI
6	Stupp R, Hegi ME, Mason WP, et al: European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10:459–466. 2009.PubMed/NCBI
7	Klayman DL: Qinghaosu (artemisinin): An antimalarial drug from China. Science. 228:1049–1055. 1985. View Article : Google Scholar : PubMed/NCBI
8	Qaderi A, Dadgar N, Mansouri H, Alavi SE, Esfahani MK and Akbarzadeh A: Modeling and prediction of cytotoxicity of artemisinin for treatment of the breast cancer by using artificial neural networks. Springerplus. 2:3402013. View Article : Google Scholar : PubMed/NCBI
9	Kim SH, Chun SY and Kim TS: Interferon-alpha enhances artemisinin-induced differentiation of HL-60 leukemia cells via a PKC alpha/ERK pathway. Eur J Pharmacol. 587:65–72. 2008. View Article : Google Scholar : PubMed/NCBI
10	Sadava D, Phillips T, Lin C and Kane SE: Transferrin overcomes drug resistance to artemisinin in human small-cell lung carcinoma cells. Cancer Lett. 179:151–156. 2002. View Article : Google Scholar : PubMed/NCBI
11	Schmuck G and Haynes RK: Establishment of an in vitro screening model for neurodegeneration induced by antimalarial drugs of the artemisinin-type. Neurotox Res. 2:37–49. 2000. View Article : Google Scholar : PubMed/NCBI
12	Ontikatze T, Rudner J, Handrick R, Belka C and Jendrossek V: Dihydroartemisinin is a hypoxia-active anti-cancer drug in colorectal carcinoma cells. Front Oncol. 4:1162014.PubMed/NCBI
13	Li YJ, Zhou JH, Du XX, et al: Dihydroartemisinin accentuates the anti-tumor effects of photodynamic therapy via inactivation of NF-κB in Eca109 and Ec9706 esophageal cancer cells. Cell Physiol Biochem. 33:1527–1536. 2014. View Article : Google Scholar : PubMed/NCBI
14	Park J, Lai HC, Singh M, Sasaki T and Singh NP: Development of a dihydroartemisinin-resistant Molt-4 leukemia cell line. Anticancer Res. 34:2807–2810. 2014.PubMed/NCBI
15	Gu HM, Warhurst DC and Peters W: Uptake of [3H] dihydroartemisinine by erythrocytes infected with Plasmodium falciparum in vitro. Trans R Soc Trop Med Hyg. 78:265–270. 1984. View Article : Google Scholar : PubMed/NCBI
16	Xie LH, Li Q, Zhang J and Weina PJ: Pharmacokinetics, tissue distribution and mass balance of radiolabeled dihydroartemisinin in male rats. Malar J. 8:1122009. View Article : Google Scholar : PubMed/NCBI
17	Kim SJ, Kim MS, Lee JW, et al: Dihydroartemisinin enhances radiosensitivity of human glioma cells in vitro. J Cancer Res Clin Oncol. 132:129–135. 2006. View Article : Google Scholar : PubMed/NCBI
18	Huang XJ, Li CT, Zhang WP, Lu YB, Fang SH and Wei EQ: Dihydroartemisinin potentiates the cytotoxic effect of temozolomide in rat C6 glioma cells. Pharmacology. 82:1–9. 2008. View Article : Google Scholar : PubMed/NCBI
19	Sun YC, Wang J, Guo CC, et al: MiR-181b sensitizes glioma cells to teniposide by targeting MDM2. BMC Cancer. 14:6112014. View Article : Google Scholar : PubMed/NCBI
20	Naito S, von Eschenbach AC, Giavazzi R and Fidler IJ: Growth and metastasis of tumor cells isolated from a human renal cell carcinoma implanted into different organs of nude mice. Cancer Res. 46:4109–4115. 1986.PubMed/NCBI
21	Buckner JC: Factors influencing survival in high-grade gliomas. Semin Oncol. 30(Suppl 19): S10–S14. 2003.
22	Curran WJ Jr, Scott CB, Horton J, et al: Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst. 85:704–710. 1993. View Article : Google Scholar : PubMed/NCBI
23	De Angelis LM: Brain tumors. N Engl J Med. 344:114–123. 2001. View Article : Google Scholar : PubMed/NCBI
24	Sai K, Li WY, Chen YS, et al: Triptolide synergistically enhances temozolomide-induced apoptosis and potentiates inhibition of NF-κB signaling in glioma initiating cells. Am J Chin Med. 42:485–503. 2014. View Article : Google Scholar : PubMed/NCBI
25	Fu J, Yang QY, Sai K, et al: TGM2 inhibition attenuates ID1 expression in CD44-high glioma-initiating cells. Neuro Oncol. 15:1353–1365. 2013. View Article : Google Scholar : PubMed/NCBI
26	Li Y and Wu YL: An over four millennium story behind qinghaosu (artemisinin) - a fantastic antimalarial drug from a traditional Chinese herb. Curr Med Chem. 10:2197–2230. 2003. View Article : Google Scholar : PubMed/NCBI
27	Rasheed SA, Efferth T, Asangani IA and Allgayer H: First evidence that the antimalarial drug artesunate inhibits invasion and in vivo metastasis in lung cancer by targeting essential extracellular proteases. Int J Cancer. 127:1475–1485. 2010. View Article : Google Scholar : PubMed/NCBI
28	Efferth T, Sauerbrey A, Olbrich A, et al: Molecular modes of action of artesunate in tumor cell lines. Mol Pharmacol. 64:382–394. 2003. View Article : Google Scholar : PubMed/NCBI
29	Stockwin LH, Han B, Yu SX, et al: Artemisinin dimer anticancer activity correlates with heme-catalyzed reactive oxygen species generation and endoplasmic reticulum stress induction. Int J Cancer. 125:1266–1275. 2009. View Article : Google Scholar : PubMed/NCBI
30	Scherz-Shouval R and Elazar Z: ROS, mitochondria and the regulation of autophagy. Trends Cell Biol. 17:422–427. 2007. View Article : Google Scholar : PubMed/NCBI
31	Wang Z, Hu W, Zhang JL, Wu XH and Zhou HJ: Dihydroartemisinin induces autophagy and inhibits the growth of iron-loaded human myeloid leukemia K562 cells via ROS toxicity. FEBS Open Bio. 2:103–112. 2012. View Article : Google Scholar : PubMed/NCBI
32	Efferth T, Briehl MM and Tome ME: Role of antioxidant genes for the activity of artesunate against tumor cells. Int J Oncol. 23:1231–1235. 2003.PubMed/NCBI
33	Kanzawa T, Germano IM, Komata T, Ito H, Kondo Y and Kondo S: Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. Cell Death Differ. 11:448–457. 2004. View Article : Google Scholar : PubMed/NCBI